New medicine to treat infections in adults
Vabomere, a combination of an antibiotic and new beta-lactamase inhibitor, addresses bacterial resistance
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Vabomere (meropenem trihydrate/vaborbactam), a new treatment option against the following infections in adults:
- Complicated urinary tract infection, including pyelonephritis, a sudden and severe infection causing the kidneys to swell and which may permanently damage them;
- Complicated intra-abdominal infection;
- Hospital-acquired pneumonia, including ventilator associated pneumonia;
- Bacteria in the blood associated with any of the infections listed above;
- Infections due to aerobic Gram-negative organisms in adults with limited treatment options.
The lack of availability of medicines to treat patients with infections caused by resistant bacteria has become a major problem in recent years. It is estimated that at least 25,000 patients in the European Union (EU) die each year from infections due to bacteria that are resistant to many medicines.
Vabomere is a fixed combination of vaborbactam, a new beta-lactamase inhibitor and meropenem, a broad-spectrum antibiotic belonging to the class of carbapenems that is already approved for use in the EU. It is a powder for concentrate for solution for infusion (drip into a vein).
Resistance to carbapenems has been increasing lately, in particular in Gram-negative bacteria, and is of major concern. Beta-lactamases are enzymes involved in bacterial resistance to these antibiotics. By inhibiting the action of beta-lactamases, vaborbactam protects meropenem from being inactivated and restores its activity against many, but not all, carbapenem-resistant pathogens.
In the clinical development program, the exposure to vaborbactam at the recommended dose was shown to be sufficient to protect the activity of meropenem against carbapenem-resistant Enterobacteriaceae. The CHMP also agreed that the studies did not indicate any major concerns regarding the safety profile of meropenem-vaborbactam.
EMA contributes to the European and global effort to tackle antimicrobial resistance. A major area of activity is to create an environment that stimulates and facilitates the development of new antimicrobials. The Agency’s activities also include the monitoring and analysis of data on antimicrobials to guide policy and research, as well as the promotion of their responsible use.
The opinion adopted by the CHMP is an intermediary step on Vabomere’s path to patient access. The opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorisation. Once the marketing authorisations has been granted, decisions about price and reimbursement will take place at the level of each Member State, taking into account the potential role/use of this medicine in the context of the national health system of that country.
- The applicant for is Rempex London Ltd.
|New medicine to treat infections in adults||(English only)||21/09/2018|
Latest News from
Security Union: EC welcomes political agreement on new rules for explosive precursors15/02/2019 16:25:00
The reinforced rules will ensure stronger safeguards & controls on the sale of dangerous chemicals that can be misused for the production of home-made explosives.
EC welcomes European Parliament's support for investment screening framework15/02/2019 15:37:00
Following the vote, the EU is one step closer to putting in place a Europe-wide framework for screening foreign direct investment.
Fair labour mobility: EC welcomes agreement on the European Labour Authority15/02/2019 13:25:00
The EC, the European Parliament and the Council havereached a provisional agreement on the EC’s proposal to establish a European Labour Authority (ELA).
EU negotiators agree to set up new European rules to improve fairness of online platforms' trading practices15/02/2019 11:43:00
The European Parliament, the Council of the EU and the EC reached a political deal on the first-ever rules aimed at creating a fair, transparent & predictable business environment for businesses and traders when using online platforms.
Agreement with Singapore set to give a boost to EU-Asia trade15/02/2019 09:25:00
The trade and investment agreements between the EU and Singapore have received the approval of the European Parliament. The Parliament has also given its green light to the Partnership and Cooperation Agreement.
Fisheries: EC welcomes provisional political agreement on new technical conservation measures14/02/2019 16:25:00
The European Parliament and the Council agreed on the EC's proposal for decentralised & simplified technical rules, giving fishermen a stronger say in deciding on the best measures for sustainable fishing adapted to their specific needs.
Digital Single Market: EU negotiators reach a breakthrough to modernise copyright rules14/02/2019 14:10:00
The European Parliament, the Council of the EU and the EC have found a political agreement to make the copyright rules fit for digital era in Europe and bring tangible benefits to all creative sectors, the press, researchers, educators, cultural heritage institutions, and citizens.
EIOPA welcomes agreement on a Pan-European Personal Pension Product14/02/2019 13:43:00
The European Insurance and Occupational Pensions Authority (EIOPA) welcomes the agreement reached by the European Parliament and the Members States on the proposal for a Pan-European Personal Pension Product, the PEPP.
EC adopts new list of third countries with weak anti-money laundering & terrorist financing regimes14/02/2019 12:25:00
The EC has adopted its new list of 23 third countries with strategic deficiencies in their anti-money laundering and counter-terrorist financing frameworks.